This website uses cookies to enhance your browsing experience, improve site performance, and gather analytics. By selecting 'Accept,' you consent to these cookies as described in our Privacy Policy.

HomeBrowseAboutFAQs
Log In
Sign Up
Non Hodgkin Lymphoma

Assessment of the Minimal Residual Disease in DLBCL From Cell-free Circulating DNA by NGS

Sponsored by Centre Henri Becquerel

About this trial

Last updated 8 years ago

Study ID

CHB13.03

Status

Completed

Type

Interventional

Phase

N/A

Placebo

No

Accepting

18-75 Years
18+ Years
All
All

Not accepting

Not accepting
Healthy Volunteers

Trial Timing

Ended 9 years ago

What is this trial about?

This is a prospective descriptive monocentric study whose purpose is to describe the clonal evolution of the mutational pattern in cfDNA of a cohort of patients with Diffuse Large B-Cell Non-Hodgkin Lymphomas (DLBCL) before, during and after standard treatment

What are the participation requirements?

Yes

Inclusion Criteria

- Age up to 18 years old

- With a diagnosis formally established of DLBCL or transformed straightaway follicular lymphoma or 3B grade follicular lymphoma or Burkitt-like lymphoma

- Eligible to a treatment by immunochemotherapy like R-CHOP, R-ACVBP or R-CHOP like

- First line of treatment

- Being able to benefit from standard extension assessment ( Fluorine-18 fluorodeoxyglucose positron emission tomography (18F-FDG-PET) and bone marrow biopsy with a bone marrow aspiration)

- Written informed consent

- Tumor biopsy used for diagnosis available

No

Exclusion Criteria

- Patient who cannot receive polychemotherapy like R-CHOP, R-ACVBP, or R-CHOP like

- Patient who cannot benefit from standard extension assessment and follow-up by with Fluorine-18 fluorodeoxyglucose positron emission tomography (18F-FDG-PET)

- Pregnant or breast-feeding woman

- Guardianship, curatorship

- Patient who cannot follow the medical procedures of the study for geographic, social, psychological,linguistic or physical reasons